9. Subject has Castrate Resistant Prostate Cancer, defined as having a rising PSA level and a testosterone level </= 50ng/dl (2.0 nM/L) while receiving androgen deprivation therapy (medical or surgical castration). Subject must also plan to receive androgen deprivation therapy throughout the study.